SLC7A5 and prostate cancer: In experiments assessing the transcription levels of SLC7A5 by TaqMan qPCR in different thyroid cancer cell lines the prostate cancer cell line LNCaP was used as a negative control [46] and the colon cancer cell line HT-29, in which LAT1 is highly and functionally expressed at the plasma membrane [31] served as positive control.